These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 16543927

  • 1. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years.
    Islam MS, Vernon SA, Negi A.
    Eye (Lond); 2007 Mar; 21(3):321-3. PubMed ID: 16543927
    [Abstract] [Full Text] [Related]

  • 2. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
    Cardillo JA, Melo LA, Costa RA, Skaf M, Belfort R, Souza-Filho AA, Farah ME, Kuppermann BD.
    Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial.
    Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A.
    Ophthalmology; 2004 Feb; 111(2):218-24; discussion 224-5. PubMed ID: 15019365
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB.
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [Abstract] [Full Text] [Related]

  • 5. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection.
    Chu YK, Chung EJ, Kwon OW, Lee JH, Koh HJ.
    Eye (Lond); 2008 Jul; 22(7):895-9. PubMed ID: 17435692
    [Abstract] [Full Text] [Related]

  • 6. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
    Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G.
    Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
    [Abstract] [Full Text] [Related]

  • 7. Cataract formation and other complications of intravitreal triamcinolone for macular edema.
    Thompson JT.
    Am J Ophthalmol; 2006 Apr; 141(4):629-37. PubMed ID: 16564796
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial.
    Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, Gaudric A, Massin P.
    Acta Ophthalmol Scand; 2006 Oct; 84(5):624-30. PubMed ID: 16965492
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.
    Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM.
    Ophthalmology; 2005 Jan; 112(1):139-43. PubMed ID: 15629834
    [Abstract] [Full Text] [Related]

  • 10. Cataract surgery after intravitreal injection of triamcinolone acetonide.
    Jonas JB, Kreissig I, Degenring RF.
    Eye (Lond); 2004 Apr; 18(4):361-4. PubMed ID: 15069430
    [Abstract] [Full Text] [Related]

  • 11. The effect of intravitreal triamcinolone on intraocular pressure.
    Kramar M, Vu L, Whitson JT, He YG.
    Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg.
    Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P.
    Am J Ophthalmol; 2006 Nov; 142(5):794-99. PubMed ID: 16978576
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
    Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M.
    Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
    [Abstract] [Full Text] [Related]

  • 14. Outcome of intravitreal triamcinolone in uveitis.
    Kok H, Lau C, Maycock N, McCluskey P, Lightman S.
    Ophthalmology; 2005 Nov; 112(11):1916.e1-7. PubMed ID: 16171868
    [Abstract] [Full Text] [Related]

  • 15. [Triamcinolone in the treatment of the diabetic macular edema--one-year results].
    Dusová J, Studnicka J, Rencová E, Korda V, Hejcmanová D.
    Cesk Slov Oftalmol; 2008 Jul; 64(4):149-52. PubMed ID: 18780654
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation.
    Negi AK, Vernon SA, Lim CS, Owen-Armstrong K.
    Eye (Lond); 2005 Jul; 19(7):747-51. PubMed ID: 15359268
    [Abstract] [Full Text] [Related]

  • 17. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection.
    Im L, Allingham RR, Singh I, Stinnett S, Fekrat S.
    J Glaucoma; 2008 Mar; 17(2):128-32. PubMed ID: 18344759
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial.
    Faghihi H, Taheri A, Farahvash MS, Esfahani MR, Rajabi MT.
    Retina; 2008 Oct; 28(9):1241-6. PubMed ID: 18626423
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.
    Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S.
    Br J Ophthalmol; 2004 Sep; 88(9):1131-6. PubMed ID: 15317702
    [Abstract] [Full Text] [Related]

  • 20. Cataract progression after intravitreal triamcinolone injection.
    Cekiç O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM.
    Am J Ophthalmol; 2005 Jun; 139(6):993-8. PubMed ID: 15953428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.